We are live on ! Find out more
Swiss National Bank

Swiss National Bank Portfolio holdings

AUM $191B
1-Year Est. Return 45.21%
 

The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.

This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+45.21%
3 Year Est. Return
+136.44%
5 Year Est. Return
+183.49%
10 Year Est. Return
+678.03%
AUM
$97.5B
AUM Growth
+$3.42B
Cap. Flow
-$3.98B
Cap. Flow %
-4.08%
Top 10 Hldgs %
19.49%
Holding
2,602
New
82
Increased
1,582
Reduced
725
Closed
96

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$249M
2
CELG
Celgene Corp
CELG
+$231M
3
MSFT icon
Microsoft
MSFT
+$171M
4
BABA icon
Alibaba
BABA
+$140M
5
AMZN icon
Amazon
AMZN
+$99.5M

Sector Composition

Rank Sector Weight
1 Technology 21.49%
2 Healthcare 14.66%
3 Consumer Discretionary 11.66%
4 Communication Services 10.19%
5 Industrials 9.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CBAY
2501
DELISTED
Cymabay Therapeutics
CBAY
$232K ﹤0.01%
118,400
+2,500
+2% +$9.39K
MDR
2502
DELISTED
McDermott International
MDR
$230K ﹤0.01%
339,611
CASA
2503
DELISTED
Casa Systems, Inc. Common Stock
CASA
$218K ﹤0.01%
53,400
GBL
2504
DELISTED
GAMCO Investors, Inc.
GBL
$211K ﹤0.01%
10,838
+1,100
+11% +$19.4K
SLDB icon
2505
Solid Biosciences
SLDB
$918M
$176K ﹤0.01%
2,640
+760
+40% +$83.9K
CYCN icon
2506
Cyclerion Therapeutics
CYCN
$16.8M
$77K ﹤0.01%
1,412
AAOI icon
2507
Applied Optoelectronics
AAOI
$11.2B
-35,100
Closed -$394K
ABEO icon
2508
Abeona Therapeutics
ABEO
$425M
-2,496
Closed -$141K
ARAY icon
2509
Accuray
ARAY
$34.9M
-163,600
Closed -$453K
ASRT
2510
DELISTED
Assertio
ASRT
-1,983
Closed -$152K
BBAR icon
2511
BBVA Argentina
BBAR
$3.53B
-133,191
Closed -$5.68M
BH icon
2512
Biglari Holdings Class B
BH
$1.21B
-1,797
Closed -$196K
CBUS icon
2513
Cibus
CBUS
$146M
-366
Closed -$103K
CTRN icon
2514
Citi Trends
CTRN
$618M
-21,586
Closed -$395K
CVEO icon
2515
Civeo
CVEO
$330M
-20,408
Closed -$311K
EVC icon
2516
Entravision Communication
EVC
$1.08B
-114,600
Closed -$364K
FET icon
2517
Forum Energy Technologies
FET
$882M
-7,106
Closed -$220K
FLNT
2518
Fluent
FLNT
$127M
-11,667
Closed -$191K
CBIO
2519
Crescent Biopharma
CBIO
$644M
-642
Closed -$277K
INO icon
2520
Inovio Pharmaceuticals
INO
$76.1M
-14,567
Closed -$358K
KALV
2521
DELISTED
KalVista Pharmaceuticals
KALV
-17,600
Closed -$204K
KLXE icon
2522
KLX Energy Services
KLXE
$46M
-7,800
Closed -$337K
KNSA icon
2523
Kiniksa Pharmaceuticals
KNSA
$5.97B
-19,500
Closed -$166K
NDLS icon
2524
Noodles & Co
NDLS
$96M
-6,125
Closed -$277K
NERV icon
2525
Minerva Neurosciences
NERV
$221M
-7,525
Closed -$467K

Similar funds

Swiss National Bank's Q4 2019 Portfolio in Review

As of Q4 2019, Swiss National Bank held 2,602 positions worth $97.5B, up 3.6% from $94.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Swiss National Bank withdrew a net $3.98B in Q4 2019, closing 96 positions and reducing 725 holdings. Its most notable exit was Celgene Corp, an estimated $231M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Swiss National Bank opened a new position in Match Group worth $14.7M.

  • Swiss National Bank's largest Q4 2019 buy was Match Group: 179,200 shares worth $14.7M.
  • Swiss National Bank added most to Bristol-Myers Squibb in Q4 2019, an estimated $114M increase.
  • Swiss National Bank's biggest Q4 2019 reduction was Apple, cutting an estimated $249M.
  • Swiss National Bank fully exited Celgene Corp in Q4 2019, selling an estimated $231M.
  • Swiss National Bank's ten largest holdings make up 19% of its $97.5B portfolio in Q4 2019.
  • Swiss National Bank opened 82 new positions and closed 96 in Q4 2019.
  • Swiss National Bank's portfolio value rose 3.6% quarter-over-quarter to $97.5B.

Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.